Geode Capital Management’s Urovant Sciences Ltd. UROV Stock Holding History

Geode Capital Management’s Portfolio UROV Stock Details UROV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-99,876	Closed	-$1.61M	–	4504
2020 Q4	$1.61M	Buy	99,876 +10,630	+12%	+$132K	﹤0.01%	3194
2020 Q3	$833K	Hold	89,246	–	–	﹤0.01%	3272
2020 Q2	$878K	Buy	89,246 +6,875	+8%	+$65.9K	﹤0.01%	3182
2020 Q1	$759K	Buy	82,371 +2,715	+3%	+$32.7K	﹤0.01%	3122
2019 Q4	$1.24M	Sell	79,656 -4,306	-5%	-$46.7K	﹤0.01%	3205
2019 Q3	$795K	Sell	83,962 -1,034	-1%	-$8.97K	﹤0.01%	3313
2019 Q2	$672K	Buy	84,996 +46,053	+118%	+$378K	﹤0.01%	3360
2019 Q1	$391K	Buy	+38,943	New	+$399K	﹤0.01%	3530

Geode Capital Management's UROV Position: Q1 2021 in Review

Geode Capital Management sold out of Urovant Sciences Ltd. (UROV) in Q1 2021, closing a stake of 99,876 shares — an estimated $1.61M sold.

Geode Capital Management first reported a position in UROV in Q1 2019 and held it in 8 quarters. The position peaked at $1.61M in Q4 2020. 0 funds tracked by Wall St. Rank hold UROV as of Q1 2021.

Geode Capital Management reported no remaining Urovant Sciences Ltd. position as of Q1 2021 after selling out during the quarter.
Geode Capital Management sold 99,876 Urovant Sciences Ltd. shares in Q1 2021, an estimated $1.61M.
Geode Capital Management first reported a position in Urovant Sciences Ltd. in Q1 2019 and held it in 8 quarters.
Geode Capital Management's Urovant Sciences Ltd. position peaked at $1.61M in Q4 2020.
0 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q1 2021.

Based on Geode Capital Management's 13F filing for Q1 2021, filed 12 May 2021.